{"id":"NCT01953913","sponsor":"Boehringer Ingelheim","briefTitle":"Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation","officialTitle":"An Open Label, Multicentre, Single Arm Trial to Assess the Safety of Afatinib for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-09-30","primaryCompletion":"2018-07-06","completion":"2018-07-06","firstPosted":"2013-10-01","resultsPosted":"2019-08-12","lastUpdate":"2019-08-12"},"enrollment":542,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":[{"type":"DRUG","name":"Afatinib","otherNames":[]}],"arms":[{"label":"Afatinib","type":"EXPERIMENTAL"}],"summary":"Primary objective of the trial is to evaluate the safety of afatinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR (Epidermal growth factor receptor) mutation(s) and have never been treated with an EGFR-TKI (tyrosine kinase inhibitor). Secondary objective is to assess the time to symptomatic progression (as judged by investigator).","primaryOutcome":{"measure":"Percentage of Participants With Serious Adverse Events (SAEs)","timeFrame":"From first drug administration up to 28 days after last drug administration, up to 1624 days.","effectByArm":[{"arm":"Afatinib","deltaMin":30.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":16},"locations":{"siteCount":33,"countries":["China","Hong Kong","India","Singapore","Taiwan"]},"refs":{"pmids":["35114807","35020119"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":164,"n":541},"commonTop":["Diarrhoea","Rash","Paronychia","Mouth ulceration","Stomatitis"]}}